Sexually Transmitted Diseases – An Underestimated Threat Lacking Interventions
Sexually transmitted diseases (STDs) represent a significant health threat given their potentially serious complications and association with increased transmission of human immunodeficiency virus (HIV). High disease burdens, low diagnosis and treatment rates, and a lack of marketed interventions for the prevention of most STDs highlight the clinical and commercial potential in this area. Scope Review of epidemiology and current treatment practice for chlamydia, gonorrhea, HPV, HSV-2 across the US, Japan, France, Italy, Germany, Spain and UK Review of current clinical practice and key drugs and vaccines in development for sexually transmitted diseases Thorough assessment of key developments, opportunities and threats shaping the sector In-depth discussion of future strategies to improve the management of sexually transmitted diseases Highlights The potential for prophylactic vaccines against STDs has been demonstrated by the success of marketed prophylactic human papillomavirus vaccines. Due to its wider serotype coverage, Merck & Co’s Gardasil continues to outperform GlaxoSmithKline’s Cervarix with annual global sales of $1. 7 billion versus $292m, respectively. Challenges for the development of vaccines against chlamydia, gonorrhea or HSV-2 include vaccine design, considering the complexity of pathogen biology and required immune response, as well as reimbursement and uptake. Successful marketing strategies could exploit the link between STDs and infertility as well as increased HIV transmission. Improvements in rapid point-of-care diagnostic tests and the development of home-testing devices would increase currently low diagnosis and treatment rates for STDs and help to prevent transmission and long-term complications. Reasons to Purchase Review the epidemiological and clinical factors driving new product decisions in STDs as well as unmet needs with current treatment options. Understand challenges, unmet needs and future opportunities by learning about the views of key opinion leaders Gain competitive advantage by identifying key product characteristics and potential roles for new therapies Source: : reportsandreports. com/ Blog: reportsnreports. wordpress. com/